Newer antipsychotics: comparative review of drug interactions

References

• Markowitz JS, Brown CS, Moore TR. Atypical antipsychotics. Part I: pharmacology, pharmacokinetics and efficacy. Ann. Phannacother 33, 73–85 (1999).
   Google Scholar
• •A useful review on novel antipsychotics.
   Google Scholar
• Brown CS, Markowitz JS, Moore TR, Parker NG. Atypical antipsychotics. Part II: adverse effects, drug interactions and costs. Ann. Pharmacother.33, 210–217 (1999).
   Google Scholar
• •A useful review on novel antipsychotics.
   Google Scholar
• Meltzer HY. Preclinical pharmacology of atypical antipsychotic drugs: a selective review. BE J: Clin. PFchiatry168\(Suppl. 2), 23–31 (1996).
   Google Scholar
• •This paper describes the pharmacodynamic properties of newer antipsychotics.
   Google Scholar
• Dunayevich E, McElroy SL. Atypical antipsychotics in the treatment of bipolar disorder: pharmacological and clinical effects. CNS Drugs 13, 433–441 (2000).
   Web of Science ®Google Scholar
• Madhusoodanan S, Brenner R, Cohen CI. Role of atypical antipsychotics in the treatment of psychosis and agitation associated with dementia. CNS Drugs 12, 135–150 (1999).
   Google Scholar
• Remington G, Kapur S. Atypical antipsychotics: are some more atypical than others? PTchophalmacology148,3–15 (2000).
   PubMed Web of Science ®Google Scholar
• Gonzalez FJ. Human cytochrome P450: Problem and prospects. Pend Pharmacol Sci. Rev 13,346–352 (1992).
   Google Scholar
• •A interesting review on the cytochrome P450 system.
   Google Scholar
• Guengerich FR Role of cytochrome P450 enzymes in drug-drug interactions. Adv. Pharmacol 43, 7–35 (1997).
   Google Scholar
• ••An outstanding article on the mechanisms of metabolically-based drug interactions.
   Google Scholar
• Nelson DR, Koymans L, Kamataki T et al P450 superfamily, update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics6, 1–42 (1996).
   PubMedGoogle Scholar
• Sproule BA, Naranjo CA, Bremner KE, Hassan PC. Selective serotonin re-uptake inhibitors and CNS drug interactions: A critical review of the evidence. Clin. Pharmacokinet. 33, 454–471 (1997).
   PubMed Web of Science ®Google Scholar
• •This article describes the basic pharmacokinetic properties of newer antipsychotics.
   Google Scholar
• Ereshefsky L. Pharmacokinetics and drug interactions: updates for new antipsychotics. j Clin. Psychiatry 57\(Suppl. 11), 12–25 (1996).
   Google Scholar
• Shen WW The metabolism of atypical antipsychotic drugs: an update. Ann. Clin. Bychiatryll, 145–158 (1999).
   Google Scholar
• Prior TI, Chue PS, Tibbo P, Baker GR. Drug metabolism and atypical antipsychotics. Eur. Neumpsychopharmacol 9,301–309 (1999).
   PubMed Web of Science ®Google Scholar
• Dahl ML, Llerena A, Bondesson U, Lindstrom L, Bertilsson L. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. BE j Clin. Pharmacol 37,71–74 (1994).
   Google Scholar
• Schotte A, Jansen PPM, Gommeren W et al Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124, 57–73 (1996).
   PubMed Web of Science ®Google Scholar
• Arnt J, Skarsfeldt T Do novel antipsychotic have similar pharmacological characteristics? A review of evidence. Aburopsychophatmacology18, 63–101 (1998).
   PubMed Web of Science ®Google Scholar
• Kapur S, Seeman P Does fast dissociation from the dopamine D2 receptor expalin the action of atypical antipsychotics? A new hypothesis. Am J. PTchiatry158, 360–369 (2001).
   Google Scholar
• •A new interesting hypothesis on the mechanism of action of atypical antipsychotics.
   Google Scholar
• Mulsant BH, Foglia JP, Sweet RA, Rosen J, Lo KH, Pollock BG. The effects of perphenazine on the concentration of nortriptyline and its hydroxymetabolites in older patients. J: Clin. Psychopharmacol 17, 318–321 (1997).
   Web of Science ®Google Scholar
• Shin JG, Soukhova N, Flockhart DA. Effect of antipsychotic drugs on human liver cytochrome P450 (CYP) isoforms in Wm preferential inhibition of CYP2D6. Drug .114tab. Dispas 27, 1078–1084 (1999).
   Google Scholar
• Ring BJ, Binkley SN, Vandenbranden M, Wrighton SA. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C19, CYP2C10, CYP2D6 and CYP3A. Br. Gun. Phalmacol 41, 181–186 (1996).
   Google Scholar
• Prakash C, Kamel A, Cui D, Whalen RD, Miceli JJ, Tweedie D. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. BE Clin. Pharmacol 49\(Suppl. 1), 35S-42S (2000).
   Google Scholar
• Smith T, Riskin J. Effect of clozapine on plasma nortriptyline concentration. Phalmacopsychiatry27, 41–42 (1994).
   PubMed Web of Science ®Google Scholar
• Tyson SC, Devane CL, Risch SC. Pharmacokinetic interaction between risperidone and clozapine. Am. j Rychiatry 152, 1401–1402 (1995).
   Google Scholar
• Koreen AR, Lieberman JA, Kronig M, Cooper TB. Cross-tapering clozapine and risperidone. Am. j Psychiatry 152, 1690 (1995).
   PubMed Web of Science ®Google Scholar
• Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics.j Clin. Rychiatry57, 129–130 (1996).
   PubMed Web of Science ®Google Scholar
• Simpson GM, Lindenmayer JP. Extrapyramidal symptoms in patients treated with risperidone. j Gun. PFhopharmacol 17, 194–201 (1997).
   Web of Science ®Google Scholar
• Edge SC, Markowitz JS, DeVane CL. Clozapine drug interactions: a review of the literature. Hum. P9rhophalmacol. 12, 5–20 (1997).
   Google Scholar
• Taylor D. Pharmacokinetic interactions involving clozapine. BE j PFCniany171, 109–112 (1997).
   Google Scholar
• Perry PJ. Therapeutic drug monitoring of atypical antipsychotics: is it of potential clinical value? CNS Drugs 13, 167–171 (2000).
   Web of Science ®Google Scholar
• Freeman DJ, Oyewumi LK. Will routine therapeutic drug monitoring have a place in clozapine therapy? Gun. Pharmacokinet. 32, 93–100 (1997).
   PubMed Web of Science ®Google Scholar
• Hiemke C, Hartter S. Pharmacokinetics of selective serotonin re-uptake inhibitors. Phalmacol Ther. 85, 11–28 (2000).
   PubMed Web of Science ®Google Scholar
• Jerling M, Lindstrom L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: Evidence from a therapeutic drug monitoring service. Ther. Drug- Monit. 16, 368–374 (1994).
   PubMed Web of Science ®Google Scholar
• Hiemke C, Weighmann H, Hartter S, Dahmen N, Wetzel H, Muller H. Elevated serum levels of clozapine after addition of fluvoxamine. j Gun. PTchopharmacol 14: 279–281 (1994).
   PubMed Web of Science ®Google Scholar
• Kuo FJ, Lane HY, Chang WH. Extrapyramidal symptoms after addition of fluvoxamine to clozapine. j Gun. Psychopharmacol 53, 483–484 (1998).
   Google Scholar
• Wetzel H, Anghelescu I, Szegedi A et al Pharmacokinetic interaction of clozapine with selective serotonin re-uptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. j Gun. PTchophalmacol. 18, 2–9 (1998).
   PubMed Web of Science ®Google Scholar
• Szegedi A, Anghelescu I, Wiesner J et al Addition of low-dose of fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry32, 148–153 (1999).
   PubMed Web of Science ®Google Scholar
• Shader RI, Greenblatt DJ. Clozapine and fluvoxamine, a curious complexity. j Gun. Psychopharmacol 18, 101–102 (1998).
   Web of Science ®Google Scholar
• Centorrino F, Baldessarini RJ, Kando J, Frankenburg FR, Volpicelli SA, Flood JG. Serum concentrations of clozapine and its metabolites: Effects of cotreatment with fluoxetine or valproate. Am. j Rychiatry 151, 123–125 (1994).
   PubMed Web of Science ®Google Scholar
• Centorrino F, Baldessarini RJ, Frankenburg F et al Serum levels of clozapine and norclozapine in patients treated with selective serotonin re-uptake inhibitors. Am.fisychiatry 153, 820–822 (1996).
   PubMed Web of Science ®Google Scholar
• Spina E, Avenoso A, Facciola G et al Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. Int. Gun. Psychopharmacol 13, 141–145 (1998).
   PubMed Web of Science ®Google Scholar
• Spina E, Avenoso A, Salemi M et al Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline. Pharmacopsychiatry33, 213–217 (2000).
   PubMed Web of Science ®Google Scholar
• Avenoso A, Facciola G, Scordo MG et al. No effect of citalopram on plasma levels of clozapine, risperidone and their active metabolites in patients with chronic schizophrenia. Gun. Drug Invest. 16, 393–398 (1998).
   Web of Science ®Google Scholar
• Taylor D, Ellison Z, Ementon Shaw L, Wickham H, Murray R. Co-administration of citalopram and clozapine: effect on plasma clozapine levels. int. Clin. PTchophalmacol 13, 19–21 (1998).
   Google Scholar
• Raaska K, Neuvonen PJ. Ciprofloxacin increases serum dozapine and N-desmethyldozapine: a study in patients with schizophrenia fix Gin Pharmacol 56,585–589 (2000).
   Google Scholar
• Vainer JL, Chouinard G. Interaction between caffeine and clozapine. j Gun. PTchophalmacol 14, 284–285 (1994).
   PubMed Web of Science ®Google Scholar
• Odom-White A, de Leon J. Clozapine levels and caffeine. j Gun. Psychiatry57, 175–176 (1996).
   Google Scholar
• Carrillo JA, Herraiz AG, Ramos SI, Benitez J. Effect of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. J. Clin. PTchophalmacol 18, 311–316 (1998).
   PubMed Web of Science ®Google Scholar
• Funderburg LG, Vertrees JE, True JE, Miller AL. Seizure following addition of erythromycin to clozapine therapy. Am. PTchiatry 151, 1840–1841 (1994).
   PubMed Web of Science ®Google Scholar
• Cohen LG, Chesley S, Eugenio L, Flood JG, Fisch J, Goff DC. Erythromycin-induced clozapine toxic reaction. Arch. Int. Med. 156, 675–677 (1996).
   PubMed Web of Science ®Google Scholar
• Hagg S, Spigset 0, Mjomdal T, Granberg K, Persbo-Lundqvist G, Dahlqvist R. Absence of interaction between erythromycin and a single dose of clozapine. Eur j Gun. Phatmacol 55, 221–226 (1999).
   Google Scholar
• Raaska K, Neuvonen PJ. Serum concentrations of clozapine and N-desmethyklozapine are unaffected by the potent CYP3A4 inhibitor itraconazole. Eur. Clin. Phalmacol 54, 167–170 (1998).
   Google Scholar
• Taylor D, Bodani M, Hubbeling A, Murray R. The effect of nefazodone on clozapine plasma concentrations. Int. Gum. PTchophalmacol 14, 185–187 (1999).
   PubMed Web of Science ®Google Scholar
• Szymanski S, Lieberman JA, Picou D, Masiar S, Cooper T A case report of cimetidine-induced clozapine toxicity. Clin. PTchiatry52, 21–22 (1991).
   PubMed Web of Science ®Google Scholar
• Haring C, Fleischhacker W, Schett P, Humpel C. Influence of plasma related variables on clozapine levels. Am. PTchiatry 147, 1471–1475 (1990).
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Guiterrez R, Way L, Meltzer HY. Relationship between clinical efficacy and clozapine concentration in plasma in schizophrenia: effect of smoking. j Gun. PTchophalmacol 13, 383–390 (1993).
   PubMed Web of Science ®Google Scholar
• McCarty RH. Seizures following smoking cessation in a clozapine responder. Pharmacopsychiatry27, 210–211 (1994).
   PubMed Web of Science ®Google Scholar
• Skogh E, Bengtsson F, Nordin C. Could discontinuing smoking be hazardous for patients administered clozapine medication ? A case report. Ther. Drug. Montt. 21, 580–582 (1999).
   Google Scholar
• Tiihonen J, Vartiainen H, Hakola Carbamazepine-induced changes in plasma levels of neuroleptics. Pharmacopsychiatry 28, 26–28 (1995).
   PubMed Web of Science ®Google Scholar
• Raitasuo V, Lehtovaara R, Huttunen OM. Carbamazepine and plasma levels of clozapine. Am. j Psychiatry152, 169 (1996).
   Google Scholar
• Junghan U, Albers M, Woggon B. Increased risk of hematological side effect in psychiatric patients treated with clozapine and carbamazepine? Pharmacopsychiatry26, 262 (1993).
   Google Scholar
• Langbehn DR, Alexander B. Increased risk of side effects in psychiatric patients treated with clozapine and carbamazepine: a reanalysis. Phatmaccpsychiatry33, 196 (2000).
   PubMed Web of Science ®Google Scholar
• Miller DD. Effect of phenytoin on plasma clozapine concentrations in two patients. Clin. Psychiatry 52, 23–25 (1991).
   PubMed Web of Science ®Google Scholar
• Facciola G, Avenoso A, Spina E, Perucca E. Inducing effect of phenobarbital on clozapine metabolism in patients with chronic schizophrenia. Ther. Drug- Montt. 20, 628–630 (1998).
   PubMed Web of Science ®Google Scholar
• Finley P, Warner D. Potential impact of valproic acid therapy on clozapine disposition. Biol. fiychiatry36, 487–488 (1994).
   PubMed Web of Science ®Google Scholar
• Longo LP, Salzman C. Valproic acid effects on serum concentrations of clozapine and norclozapine. Am. j Psychiatry 152, 650 (1995).
   PubMed Web of Science ®Google Scholar
• Facciola G, Avenoso A, Scordo GM et al Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders. Ther. Drug- Montt. 21, 341–345 (1999).
   PubMed Web of Science ®Google Scholar
• DeVane CL, Nemeroff CB. An evaluation of risperidone drug interactions. j Clin. fiychopharmacol 21, 408–416 (2001).
   PubMed Web of Science ®Google Scholar
• Spina E, Avenoso A, Facciola G et al. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. PTchopharmacology153, 238–243 (2001).
   PubMed Web of Science ®Google Scholar
• Spina E, Avenoso A, Facciola G, Scordo MG, Ancione M, Madia A. Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. Ther. Drug Montt. 23, 223–227 (2001).
   Google Scholar
• Spina E, Avenoso A, Scordo MG et al Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. j Clin. Rychopharmacol (submitted).
   Google Scholar
• Bork JA, Rogers T, Wedlund PJ, De Leon J. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. Clin. Psychiatry 60, 469–476 (1999).
   Google Scholar
• Lane RM. Pharmacokinetic drug interaction potential of selective serotonin re-uptake inhibitors. Int. Clin. Bychophatmacol 11\(Suppl. 5), 31–61 (1996).
   Google Scholar
• Sommers DK, Snyman JR, van Wyk M, Blom MW Huang ML, Levron JC. Lack of effect of amitriptyline on risperidone pharmacokinetics in schizophrenic patients. Int. Glitz Bychophannacol 12, 141–143 (1997).
   Google Scholar
• Loonen AJ, Doorschot CH, Oostelbos MC, Sitsen JM. Lack of drug interaction between mirtazapine and risperidone in psychiatric patients. Eur NeuropTchophalmacol 10, 51–57 (1999).
   PubMed Web of Science ®Google Scholar
• Spina E, Avenoso A, Scordo MG, Ancione M, Madia A, Levita A. No effect of reboxetine on plasma concentrations of clozapine, risperidone and their active metabolites. Ther. Drug- Montt. (In Press).
   Google Scholar
• De Leon J, Bork J. Risperidone and cytochrome P4503A. j Clin. PTchiatry58, 450 (1997).
   Google Scholar
• Spina E, Avenoso A, Facciola G et al Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. Ther Drug Montt. 22, 481–485 (2000).
   PubMed Web of Science ®Google Scholar
• Spina E, Scordo MG, Avenoso A, Perucca E. Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity. .1. Clin. fiychopharmacol 21, 108–109 (2001).
   Google Scholar
• Maenpaa J, Wrightson S, Bergstrom R et al Pharmacokinetic (PK) and pharmacodynamic (PD) interactions between fluvoxamine and olanzapine (abstract). Clin. Phatmacol Ther. 61, 225 (1997).
   Web of Science ®Google Scholar
• De Jong J, Hoogenboom B, van Troostwijck LD, De Hann L. Interaction of olanzapine with fluvoxamine. Psychopharmacology 156, 219–220 (2001).
   Google Scholar
• Markowitz JS, DeVane CL. Suspected ciprofloxacin inhibition of olanzapine resulting in increased plasma concentrations. j Clin. Rychopharmacol 19, 289–291 (1999).
   PubMed Web of Science ®Google Scholar
• Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine: pharmacokinetic and pharmacodynamic profile. Clin. Pharmacokinet. 37, 177–193 (1999).
   PubMed Web of Science ®Google Scholar
• Lucas RA, Gilfillan DJ, Bergstrom RE A pharmacokinetic interaction between carbamazepine and olanzapine: Observations on possible mechanisms. Eur. Clin. Pharmacol 54, 639–643 (1998).
   Web of Science ®Google Scholar
• Olesen OV, Linnet K. Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication. Ther. Drug- Montt. 21, 87–90 (1999).
   PubMed Web of Science ®Google Scholar
• Callaghan JT, Cerimele BJ, Kassahun KJ et al Olanzapine: interaction study with imipramine. j Clin. Pharmacol 37, 971–978 (1997).
   PubMed Web of Science ®Google Scholar
• Dev V, Raniwalla J. Quetiapine: a review of its safety in the management of schizophrenia. Drug- Sal 23, 295–307 (2000).
   PubMed Web of Science ®Google Scholar
• Wong YVVJ, Yeh C, Thyrum PT The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine. j Clin. Psychopharmacol 21, 89–93 (2001).
   PubMed Web of Science ®Google Scholar
• Potkin SG, Thyrum PT, Yeh C. The safety and pharmacokinetics of quetiapine when co-administered with haloperidol, risperidone, or thioridazine. j Clin. Psychopharmacol (In press).
   Google Scholar
• Strakowski SM, Kech PE Jr., Wong YVVJ. The effect of multiple doses of cimetidine on the steady-state pharmacokinetics of quetiapine in men with selected psychotic disorders. Psychopharmacology (In press).
   Google Scholar
• Potkin SG, Thyrum PT, Yeh C. Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. j Clin. Psychopharmacol (In press).
   Google Scholar
• Wilner KD, Hansen RA, Folger CJ, Geoffroy P. The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid. BE j Clin. Pharmacol 49\(Suppl. 1), 57S-60S (2000).
   Google Scholar
• Miceli JJ, Smith M, Robarge L, Morse T, Laurent A. The effects of ketoconazole on ziprasidone pharmacokinetics: a placebo-controlled crossover study in healthy volunteers. BE j Clin. Pharmacol. 49 (Suppl. 1), 71S-76S (2000).
   Google Scholar
• Miceli JJ, Anziano RJ, Robarge L, Hansen RA, Laurent A. The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. BE j Clin. Pharmacol. 49 (Suppl. 1), 65S-70S (2000).
   Google Scholar
• Jackson CW, Markowitz JS, Brewerton TD. Delirium associated with clozapine and benzodiazepine combinations. Ann. Clin. PFhiatry7, 139–141 (1995).
   Google Scholar
• Klimke A, Klieser E. Sudden death after iv. application of lorazepam in a patient treated with clozapine. Am. J. Psychiatry 151, 780 (1994).
   PubMed Web of Science ®Google Scholar
• Tupala E, Niskanen L, Tiihonen J. Transient syncope and ECG changes associated with concurrent administration of clozapine and diazepam. J. Clin. Psychiatry60, 619–620 (1999).
   Google Scholar
• Beasley CM, Tollefson G, Tran P, Satterlee W Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacol 14, 111–123 (1996).
   PubMed Web of Science ®Google Scholar
• Blake LM, Marks RC, Luchins DJ. Reversible neurologic symptoms with clozapine and lithium. J. Clin. Psychopharmacol. 12, 297–299 (1992).
   Google Scholar
• Garcia G, Crismon M, Dorson P. Seizures in two patients after the addition of lithium to a clozapine regimen. J. Clin. Psychopharmacol. 14, 426–428 (1994).
   Google Scholar
• Tohen M, Zarate CA, Centorrino F, Hegarty JI, Froeschl M, Zarate SB. Risperidone in the treatment of mania. J. Clin. PTchiatry57, 249–253 (1996).
   PubMed Web of Science ®Google Scholar
• Swanson CL, Price WA, McEvoy JP Effects of concomitant risperidone and lithium treatment. Am. Psychiatry152, 1096 (1996).
   Web of Science ®Google Scholar
• Chen B, Cardasis W Delirium induced by lithium and risperidone combination. Am PTchiatry153, 1233–1234 (1996).
   PubMed Web of Science ®Google Scholar
• Madhusoodanan S, Brenner R, Suresh P et al Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study. Ann. Clin. Psychiatry 12, 11–18 (2000).
   PubMedGoogle Scholar
• Aronowitz JS, Chakos MET, Safferman AZ, Lieberman JA. Syncope associated with the combination of clozapine and enalapril. Clin. Psychophalmacol. 14, 429–430 (1994).
   PubMed Web of Science ®Google Scholar